Total Funding
48
80
Total FundingPrivate Equity raised
Growth Score
-12 pts
Heat Score
4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
33979
Remegen is a biotech company focused on discovering and developing a new generation of targeted therapies for the treatments of cancer.
- Jianmin Fang: Co-Founder, CEO and CSO
- Xiaoming Yang: Chief Manufacturing OfficerPast Role: Just - Evotec Biologics, Sr. VP for Process and Product Development Biosimilar
About the Company
RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates
(ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.
